The free dividend tracker to help you grow your wealth. Link your brokerage accounts and MerryDiv automatically syncs your holdings and dividends.
Data last updated: Sep 06, 2026
Snapshot (as of Sep 06, 2026): Orion Oyj (ORINY) pays a $0.86 annual dividend, yielding 2.16% at $45.77/share. Next ex-dividend date 2026-03-26. Source: Yahoo Finance, aggregated by MerryDiv.
Dividend Yield: 2.16%
Annual Dividend: $0.86 per share
Payout Ratio: 41.3%
Ex-Dividend Date: 2026-03-26
Sector: Healthcare
Years of Dividend History: 11
Orion Oyj dividend income comes from a Finnish pharmaceutical company founded in 1917, with a portfolio spanning cancer therapies like Nubeqa, Parkinson's treatments, and veterinary medicines sold across Europe and North America. ORINY currently pays $0.86 per share on a trailing annual basis, with the next ex-dividend date set for March 26, 2026. The yield sits at 2.16%, a moderate figure that reflects a business operating across both prescription and over-the-counter healthcare markets. A beta of 0.288 points to low price volatility, which suits income investors who prioritize steadiness over rapid capital appreciation.
Orion Oyj pays out 41.3% of earnings as dividends, a payout ratio classified as moderate (40-60%). That level leaves meaningful earnings retained within the business, and Orion Oyj's product mix, spanning essential medications for intensive care sedation, Parkinson's disease, and chronic respiratory conditions like asthma and COPD, supports recurring demand. Orion Oyj dividend safety is further reinforced by the company's API manufacturing and contract services, which add revenue diversification beyond branded drugs. The most data-supported pressure point is currency exposure: ORINY reports in euros but pays dividends in U.S. dollars, meaning exchange rate shifts directly affect the per-share amount received by American investors.
Orion Oyj dividend history shows a CAGR of 2.7% per year from 2016 to 2025. Per-share payments grew from $0.7388 to $0.9387 over that window (2026 is a partial year and excluded from the growth calculation). The largest annual increase in the window was 95.5% in 2020, though the data also contains at least one year-over-year decline exceeding 5%, so growth has not been linear. Three consecutive years of dividend increases run through the most recent complete data.
| Period | CAGR | From | To |
|---|---|---|---|
| 3-Year | +3.3% | $0.85 (2022) | $0.94 (2025) |
| 5-Year | -10.6% | $1.64 (2020) | $0.94 (2025) |
ORINY fits dividend investors who want pharmaceutical sector exposure with low price volatility and a moderate income stream. The yield of 2.16% sits above the stock's own 5-year average of 1.93%, meaning the current entry point offers slightly more income than the historical norm. The payout ratio of 41.3% leaves room to sustain payments without straining earnings. Growth is slow at 2.7% per year, and that limits how quickly income compounds over time. What an investor gets here is a low-beta healthcare payer with a moderate (2-4%) yield and a product base anchored in specialty and essential medicines. The trade-off is modest dividend growth rather than rapid income acceleration.
| Payment Date | Amount per Share |
|---|---|
| 2026-03-26 | $0.5178 |
| 2025-10-16 | $0.4749 |
| 2025-04-07 | $0.4638 |
| 2024-10-16 | $0.4357 |
| 2024-03-21 | $0.4375 |
| 2023-03-23 | $0.8699 |
| 2022-03-24 | $0.8517 |
| 2021-03-26 | $0.8902 |
| 2020-05-07 | $0.8098 |
| 2020-03-26 | $0.8335 |
| Year | Total Dividends |
|---|---|
| 2026 | $0.5178 |
| 2025 | $0.9387 |
| 2024 | $0.8732 |
| 2023 | $0.8699 |
| 2022 | $0.8517 |
Project income from ORINY with the ORINY dividend calculator or track your full portfolio with the dividend tracker.